Evidence map›Paper›PMID 34973152›Full record

ReviewReproductive sciences (Thousand Oaks, Calif.)2022

The Role of miRNA in Ovarian Cancer: an Overview.

Lihui Zhao, Xiaolei Liang, Liyan Wang, Xuehong Zhang

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Reproductive sciences (Thousand Oaks, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. MiRNA-based drugs: challenges and delivery strategies.Applied microbiology and biotechnology · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lihui ZhaoKey Laboratory for Reproductive Medicine and Embryo of Gansu, First Affiliated Hospital, Lanzhou University, No.1, Donggangxi Rd, Chengguan District, Lanzhou City, Gansu, 730000, People's Republic of China.
Xiaolei LiangKey Laboratory for Reproductive Medicine and Embryo of Gansu, First Affiliated Hospital, Lanzhou University, No.1, Donggangxi Rd, Chengguan District, Lanzhou City, Gansu, 730000, People's Republic of China.
Liyan WangKey Laboratory for Reproductive Medicine and Embryo of Gansu, First Affiliated Hospital, Lanzhou University, No.1, Donggangxi Rd, Chengguan District, Lanzhou City, Gansu, 730000, People's Republic of China.
Xuehong ZhangKey Laboratory for Reproductive Medicine and Embryo of Gansu, First Affiliated Hospital, Lanzhou University, No.1, Donggangxi Rd, Chengguan District, Lanzhou City, Gansu, 730000, People's Republic of China. zhangxueh@lzu.edu.cn.ORCID 0000-0002-7216-0383
Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is a highly malignant disease that seriously threatens women's health and poses challenges for clinicians. MicroRNAs (miRNAs) have recently been intensively studied in the field of oncology due to their regulatory roles in gene expressions through RNA degradation and/or translation inhibition. This review summarizes the current studies on miRNAs in OC and introduces the latest updates of miRNAs in the early screening, treatment, and prognostic prediction of OC, thereby demonstrating the clinical significance of miRNAs in OC. Further exploration on potential targets of miRNAs in OC may provide new insights on optimizing the diagnosis and treatment of OC. MiRNAs are important driving factors for the progression of OC and the dysregulation of miRNAs can serve as biomarkers in the diagnosis, treatment and prognosis of OC. Therefore, miRNAs are potential biological targets for early screening, targeted therapy, drug resistance monitoring, and prognosis improvement in malignancies such as OC.

Indexed as

MicroRNAsOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleGene Expression Regulation, NeoplasticHumansPrognosisMicroRNAsmiRNAOvarian cancerPrognosisTreatment

Identifiers

PMID34973152
PMCPMC9537199
OpenAlexW4205515227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.